ClinicalTrials.gg
RecruitingNCT06902766FrenchCareUpdated Oct 16, 2026

Towards Digital Management of Paediatric Asthma

An interventional study of Active telemonitoring using real-time data from digital inhalers. and Standard in Pediatric Asthma, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 6 under way, none of them phase 3. Asthma · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
10th of 13
50 · median 90
Started
2025
the only one that year
No phase
8 of 31
1 open now
Registered
31st of 31
by date

Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 31st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This pilot study aims to explore whether a digital approach to managing childhood asthma using connected inhalers and video consultations triggered by alerts from these devices - could work as well as standard in-person care. The connected inhalers track when children use their daily prevention medication and their rescue medication for asthma symptoms. If a child misses several days of prevention medication or uses their rescue inhaler frequently, their doctor receives an alert and can schedule a video consultation to adjust their treatment. Fifty children aged 4-12 years with asthma will participate for 8 months, with half using this digital system and half receiving usual care. The study will measure whether this new approach is practical and acceptable to families and doctors, and will look at its effects on asthma control, quality of life, and healthcare use. The results will help design a larger study to fully test if this digital approach could improve asthma care for children.

Read the detailed description

Asthma is the most common chronic illness in children. In France, two-thirds of children have uncontrolled asthma, meaning they experience symptoms and occasional asthma attacks.

The digital revolution has enabled the development of connected devices, particularly smart inhalers, which collect objective information for assessing asthma from patients' homes. The Covid-19 pandemic has further accelerated the adoption of telemedicine. These new approaches represent a significant shift in paediatric asthma management, offering opportunities for more effective treatment methods.

As a precursor to a larger investigation, this pilot study hypothesises that digital asthma management using proactive remote care through telemedicine consultations triggered by connected device alerts may improve childhood asthma control compared to current management approaches.

03

Conditions studied

  • Pediatric Asthma

Browse trials for

Keywords

  • Pediatric asthma
  • Digital revolution
  • Digital inhaler
04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 4 to 12, whose asthma has been diagnosed by a physician
  • Followed up for their asthma by a pediatrician or pediatric pulmonologist
  • With asthma severity corresponding to GINA grades 2, 3 or 4 (Global Asthma Initiative Guidelines)
  • Whose controller and reliever treatments are administered using pressurized metered-dose inhalers (p-MDIs)
  • With social security
  • Whose parents or legal guardian(s):

    • Have given their written and for their child's participation and their participation,
    • Have a smartphone in the household that can download the application and is compatible with it,
    • Are capable, in the opinion of the investigator, of understanding the use of the mobile application and module FRENCH CARE specifically dedicated to the research and the digital inhalers provided.

Non-inclusion Criteria:

  • Patients with another pathology that could interfere with the evaluation of the endpoints (e.g, bronchopulmonary dysplasia, cystic fibrosis, etc.)
  • Patients whose parents or legal representative(s) are, in the opinion of the investigator, unable to understand the purpose of the study and/or express their consent.
  • Patients benefiting from State Medical Aid

Exclusion criteria

Exclusion Criteria:

- Patient who did not use the system within 15 days of the inclusion visit

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Digital medicine

    Active telemonitoring using real-time data from digital inhalers

    Device: Active telemonitoring using real-time data from digital inhalers.

  • Active comparator
    Standardized medicine

    The patients are monitored as usual according to the standard care protocol. Patients will receive 2 digital inhalers, but only to record their treatment use.

    Other: Standard

Interventions

  • DeviceActive telemonitoring using real-time data from digital inhalers.

    Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI,one for the controller the other for the reliever treatment. Active telemonitoring using real-time data from digital inhalers Investigators will be alerted by email if a child: * fails to take his or her controller treatment for 4 continuous days and/or * uses \> 4 doses of reliever treatment over 24 hours * uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment). For alert (2), a teleconsultation will be scheduled within 2 working days to assess and adapt treatment as needed. Emergency treatment may be adjusted for approximately one week. Alerts within the following 7 days will be considered part of the same clinical episode. For alerts (1) and (3), a teleconsultation will be scheduled within 7 working days to assess and adapt management as needed.Spirometry and pulse oximetry if needed.

  • OtherStandard

    Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers

06

What researchers measure

Primary outcomes

  1. Change in asthma severity measured by the Composite Asthma Severity Index (CASI)

    The CASI is a validated composite score that evaluates asthma severity by incorporating measures of asthma symptoms, exacerbations, lung function, and treatment level. The change in CASI score will be compared between groups, calculated as the difference between the final score (at 8 months) and the baseline score. Lower scores indicate less severe asthma. The CASI ranges from 0 to 17, with higher scores meaning a higher severity (worse outcome).

    Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group

Secondary outcomes

  1. Asthma control

    Evolution in the overall Childhood Asthma Control Test (c-ACT) score. The c-ACT (Childhood Asthma Control Test) will be used to evaluate the evolution of asthma control. The c-ACT ranges from 0 min to 27 max, with higher scores meaning better asthma control (better outcome).

    Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group

  2. Severe exacerbations requiring oral steroids

    Severe exacerbations (defined as an exacerbation requiring oral corticosteroid therapy): number of severe exacerbations per patient and percentage of patients with at least one severe exacerbation

    Time frame: During the eight-month follow up period in each group

  3. Severe exacerbations requiring emergency department visit and/or hospital admission.

    Severe exacerbations requiring emergency department visits and/or hospitali admission: number per patient and percentage of patients with at least one

    Time frame: During the eight-month follow up period in each group

  4. Children's lung function

    Evolution of lung function assessed by the predicted percentage of the forced expiratory volume in one second (FEV1) in children aged 7 to 12 years

    Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end study) in each group

  5. Quality of life questionnaire

    Children (aged 7 -12 years) were assessed by the mini Pediatric Asthma Quality of Life Questionnaire (mPAQLQ). Their parents were assessed by the Pediatric Asthma Caregivers' Quality of Life.

    Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group

  6. Adherence

    The adherence of patients to their maintenance treatment, automatically recorded via digital inhalers, defined as the number of doses taken divided by the number of doses prescribed x 100: average percentage of adherence

    Time frame: During the eight-month follow up period in each group

  7. Reliever treatment

    Use of reliever treatment (salbutamol) is automatically recorded via digital inhalers: average number of uses per each patient

    Time frame: During the eight-month follow up period in each group

  8. Number of teleconsultations/consultations

    Average number of consultations/teleconsultations per patient, scheduled and unscheduled, and their average cumulative duration per patient

    Time frame: During the eight-month follow up period in each group

  9. Children participation

    The child's speaking time compared to the total speaking time (child + parent + doctor), expressed as a percentage was determined from video recordings. The number of the child's speech turns compared to the total number of speech turns (child + parent + doctor), expressed as a percentage. The number of complete thoughts, or "utterances", of the child compared to the total number of complete thoughts, expressed as a percentage. The child's non-verbal communication, analyzed by a module of the Roter Interactive Assessment System

    Time frame: During the eight-month follow up period in each group

  10. Absenteeism

    Number of days of asthma-related absenteeism (from school for children and work for parents), per patient

    Time frame: During the eight-month follow up period in each group

  11. Satisfaction of parents

    Assessed by the proportion of parents in the experimental group responding on a custom questionnaire that they wish to continue the digital management experience and the reason for their choice

    Time frame: After 8 months (+/- 1 month) (end of study)

  12. Satisfaction of doctors

    Assessed by the proportion of doctors in the experimental group responding on a custom questionnaire that they wish to continue the digital management experience and the reason for their choice

    Time frame: After 8 months (+/- 1 month) (end of study)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 20 months is below that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jan 2027 → Jul 2027 and completion Jan 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Jul 2027was Jan 2027
CompletionEst.
Jul 2027was Jan 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Jul 2027
Oct 16, 2026
Study completion
Jan 2027→Jul 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Jan 2027→Jul 2027
    Study completion Jan 2027→Jul 2027
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06902766
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Nov 25, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

David DUMMOND, MD, PhD
Contact
david.drummond@aphp.fr
01 87 89 20 28 ext. +33
sarah BOUCHARD, Project manager
Contact
sarah.bouchard@ahp.fr
01 42 19 28 79 ext. +33
David DUMMOND, MD, PhD
principal investigator · Hôpital Necker Enfants Malades AP-HP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion